Tumor Neoantigens: When Too Much of a Good Thing Is Bad

Publication date: 11 November 2019Source: Cancer Cell, Volume 36, Issue 5Author(s): Anne Trinh, Kornelia PolyakImmunotherapy has been the most effective in tumors with high mutational burden. However, a recent study in Cell by Wolf et al. demonstrates that high intratumor heterogeneity (ITH) for cancer neoantigens paradoxically attenuates anti-tumor immune responses, suggesting a need to quantify ITH to improve patient selection for checkpoint blockade therapy.
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research